axicabtagene ciloleucel
gilead,daiichi sankyo
['axi-cel', 'lymphoma']
axi-cel has demonstrated promising efficacy and acceptable safety in patients with relapsed/refractory primary and secondary cns lymphoma, according to data from a phase 1 clinical trial presented in an oral session at #ash22 read more: 
CGTLive™ delivers quality and relevant information to healthcare professionals on cell, gene, regenerative, and engineered medicines to ultimately improve care.